Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01764737 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase 1 study of Multiple Sclerosis, sponsored by Vaccinex.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 10
- Study locations
NCT01764737: Completed Phase 1 study of Multiple Sclerosis, sponsored by Vaccinex.
NCT01764737 is a Phase 1 study of Multiple Sclerosis that has completed, run by Vaccinex. The registered enrollment target is 50 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (91% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01764737, a Phase 1 study of Multiple Sclerosis, has completed, sponsored by Vaccinex.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability of IV administration of VX15/2503 in patients with multiple sclerosis. The escalation part of the study will determine the maximum tolerated dose (MTD) or the Maximum Administered Dose if no MTD is found.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VX15/2503
Study Locations (10)
New York
- MS Center of Northeastern NY/Empire Neurology - Latham
- University of Rochester Medical Center - Rochester
Alabama
- North Central Neurology Associates, PC - Cullman
Colorado
- University of Colorado Hospital, Aschutz Inpatient Pavilion - Aurora
Indiana
- Indiana University Health Neuroscience Center - Indianapolis
Kansas
- University of Kansas Medical Center - Kansas City
Michigan
- Wayne State University - University Health Center - Detroit
North Carolina
- The Neurological Institute, PA - Charlotte
Ohio
- The Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
What the finished NCT01764737 record still lists
NCT01764737 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01764737 lists 10 locations in 9 states (New York, Alabama, Colorado).
Frequently Asked Questions
What is clinical trial NCT01764737 about?
NCT01764737 is a clinical study titled "Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS". The purpose of this study is to evaluate the safety and tolerability of IV administration of VX15/2503 in patients with multiple sclerosis. The escalation part of the study will determine the maximum tolerated dose (MTD) or the Maximum Administered Dose if no MTD is found.
What is the current status of trial NCT01764737?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2012-12. Estimated completion is 2014-11.
What conditions does trial NCT01764737 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT01764737?
The interventions under investigation include: Placebo (DRUG), VX15/2503 (DRUG).
Who is sponsoring clinical trial NCT01764737?
This trial is sponsored by Vaccinex, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01764737 being conducted?
This trial has 10 study locations across Alabama, Colorado, Indiana, Kansas, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01764737's enrollment target sits among peer trials
50 178th of 315 higher than 131 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
RECRUITING · Phase 1
-
Molecular Imaging of NET Using [C-11]MRB-PET in MS
RECRUITING · Phase 1
-
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia